Special report: Creso Pharma has signed a major deal with health and wellness company Pharmacare Europe to market and distribute its hemp-based human nutraceutical product cannaQIX® and other products in the United Kingdom.

The cannaQIX® range will be sold under the Pharmacare umbrella brand Naturopathica, setting the scene for Creso Pharma’s (ASX:CPH) presence in wider European markets.

It’s the latest overseas play for the medicinal cannabis company, which recently launched its cannaQIX 50 lozenges in New Zealand.

The cannaQIX® products are cannabidiol hemp-based nutraceuticals that use Creso’s proprietary drug delivery technology.

CBD or cannabidiol is one of at least 113 active cannabinoids identified in cannabis. It has well-researched medicinal benefits — but unlike another cannabinoid, tetrahydrocannabinol (THC), it doesn’t get you high.

The products contain hemp extract with CBD, vitamins and zinc, aimed at reducing stress and supporting mental and nervous system functions.

The cannaQIX® range of products are well tolerated, non-euphoric, non-addictive and sugar free.

Pharmacare is a key distributor to major UK and European retailers with more than 10,000 points of sale on the continent. The launch is planned for October 2018.

“Pharmacare’s success comes from its innovative nature, which fits well with our own passion for innovation, said Creso’s CEO and co-founder Dr Miri Halperin Wernli.

“We see this partnership as a significant milestone in expanding our networks and positioning in the UK and Europe more broadly,” she said.

“I strongly believe that cannabis evolves to consumer branded products with varying drug delivery methods to suit everyone’s different preferences and needs.

“With cannaQIX® we offer consumers  a safe and effective certified food supplement with CBD which has broad market access without the need for medical prescription.”

Trishina Singh of Pharmacare Europe said: “We are looking forward to working with Creso Pharma and working on their exciting, innovative and diverse product portfolio — we believe it will be a really successful collaboration”.


This special report is brought to you by Creso Pharma.

This advice has been prepared without taking into account your objectives, financial situation or needs. You should, therefore, consider the appropriateness of the advice, in light of your own objectives, financial situation or needs, before acting on the advice.

If this advice relates to the acquisition, or possible acquisition, of a particular financial product, the recipient should obtain a disclosure document, a Product Disclosure Statement or an offer document (PDS) relating to the product and consider the PDS before making any decision about whether to acquire the product.